First patient dosed in Phase 1 trial for GMI-1271

GlycoMimetics (GLYC +0.7%) reports that the first healthy volunteer has been dosed in a Phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, an E-selectin antagonist the company is developing for various cancers.

The single-site 28-patient trial will assess three dosages of GMI-1271. The company expects final results in 2H 2014.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs